Business Wire

BLUETTI

Share
What to Expect On BLUETTI Prime Day 2022

Do I have to be an Amazon Prime Member to take advantage of BLUETTI Prime Day deals?

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220710005073/en/

The short answer: nope. But if you’d like to grab the Prime Day sales only on Amazon , you’ll need to be an Amazon Prime Member.

BLUETTI confirms its annual shopping event - BLUETTI Prime Day date on July 5 - 15. To help you narrow things down, they've collected the best deals on their official website , from solar power stations, solar panels to various accessories worth your money.

The Best Prime Day Deals From BLUETTI

AC200P - The Most Popular 2kWh Solar Generator Now At The Lowest Price Ever - 1.699€ (was 1.999€)

Packed with a 2kW AC pure sine wave inverter, an enormous 2kWh capacity, and utilizing the most durable, safest LiFePO4 battery chemistry, the BLUETTI AC200P is undoubtedly the most cost-effective solar generator .

It can power all your needs from a household fridge to an 8.000 BTU portable air conditioner without breaking a sweat. Recharging by solar at a blistering speed up to 700W. You can juice up AC200P from zero to full in less than 4 hours with free, clean solar power alone!

AC200MAX - All-round Upgraded Power Beast - 2.099€ (was 2.399€)

With two expansion battery ports, the AC200MAX welcomes up to two BLUETTI B230 (2048Wh each) or B300 (3072Wh each) battery modules, allowing you to build on your system up to 8192Wh!

The AC200MAX allows up to 900W solar input and 400W via the AC wall charger, giving you a stunning 1300W total charging input to recharge it in less than 2 hours.

BLUETTI AC300 & B300 - Power Anything Imaginable - 3.899€ (was 4.299€)

Unlike any BLUETTI solar generator products, the AC300 has no built-in battery, bringing it unprecedented mobility and uniqueness. Every AC300 can accept up to 4 B300 (3072Wh each) battery modules, adding up to a groundbreaking 12288Wh capacity – Covering your whole family’s basic needs for DAYS during emergencies or power outages!

Time to plug into full-time solar life! BLUETTI AC300 is now capable of receiving 2400W of unrivaled solar charging input. The advanced MPPT controller lets you juice up a B300 (3072Wh) battery module as soon as 1,5hrs only with sunshine!

Other units highly recommended on BLUETTI UK & EU Prime Day 2022:

EB55 - 537Wh, 700W | Portable Solar Generator - £549 (was £599);
EB70 - 716Wh, 1000W | Portable Power Station - £649 (was £739);
B230 - 2048Wh LFP Expansion Battery - £1399 (was £1499);
EP500Pro - 5100Wh, 3000W | Home Backup Power - £5399 (was £5999)
AC200MAX & B230 - 4096Wh, 2200W | Portable Solar Generator - £3199 (was £3499)

EB55 - 537Wh, 700W | Portable Solar Generator - 599€ (was 649€);
EB70 - 716Wh, 1.000W | Portable Power Station - 699€ (was 749€);
B230 - 2.048Wh LFP Expansion Battery - 1.399€ (was 1.599€);
EP500Pro 5.100Wh, 3.000W | Home Backup Power - 5.399€ (was 5.999€)
AC200MAX & 2/B230 & 3/SP200 - 6.144Wh, 2.200W | Bundles - 6.394€ (was 8.249€)

About BLUETTI

With over 10 years of industry experience, BLUETTI has tried to stay true to a sustainable future through green energy storage solutions for both indoor and outdoor use while delivering an exceptional eco-friendly experience for everyone and the world. BLUETTI is making its presence in 70+ countries and is trusted by millions of customers across the globe. For more information, please visit BLUETTI online.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces Positive CHMP Opinion for PYRUKYND® (mitapivat) for Adults with Thalassemia17.10.2025 14:15:00 CEST | Press release

Avanzanite entered an exclusive partnership with Agios in June 2025 to manage PYRUKYND commercialization across Europe European Commission will now review the CHMP’s opinion, with the final decision expected by early 2026 PYRUKYND is currently approved in Europe for adults with PK deficiency; thalassemia would represent its second indication, pending European Commission approval Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the new indication for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for t

Kinaxis Accelerates Agentic Era for Supply Chain Orchestration with the Launch of Maestro Agents17.10.2025 13:00:00 CEST | Press release

AI agents that plan with you, not just for you, empower the customer journey to a next generation of the adaptive supply chain Kinaxis® Inc. (TSX: KXS), a global leader in supply chain orchestration, today announced Maestro Agents, marking the next milestone in AI-enabled decision intelligence for supply chains. Now available to Kinaxis customers and embedded natively in Kinaxis Maestro®, these AI-powered context aware digital co-workers help planners move faster from issue to action, turning disruption into opportunity, and strengthening the resilience of the supply chains that power the global economy. “Kinaxis agents are already helping our planning team collaborate more effectively with customers and contract manufacturers,” said John Finnigan, Senior Director, Advanced Planning at Jabil. “With human-in-the-loop safeguards, we’re reaching decisions faster today and see strong potential to build a more resilient and networked supply chain.” Maestro Agents advance the customer journe

SLB Announces Third-Quarter 2025 Results17.10.2025 12:50:00 CEST | Press release

Revenue of $8.93 billion increased 4% sequentially and decreased 3% year on year GAAP EPS of $0.50 decreased 32% sequentially and 40% year on year EPS, excluding charges and credits, of $0.69 decreased 7% sequentially and 22% year on year Net income attributable to SLB of $739 million decreased 27% sequentially and 38% year on year Adjusted EBITDA of $2.06 billion was flat sequentially and decreased 12% year on year Cash flow from operations was $1.68 billion and free cash flow was $1.10 billion, including $153 million of acquisition-related payments Board approved quarterly cash dividend of $0.285 per share SLB (NYSE: SLB) today announced results for the third-quarter 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251015948706/en/ The exterior of the SLB headquarters in Houston, Texas. Third-Quarter Results(Stated in millions, except per share amounts)Three Months EndedChangeSept. 30, 2025Jun. 30, 2025Sept. 30, 2024Se

Dompé's Program in NAION Selected for Landmark FDA Commissioner’s National Priority Voucher Program17.10.2025 02:42:00 CEST | Press release

One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who urgently need them.With this selection, Dompé receives a voucher shortening the marketing application review from the standard 10–12 months to just 1–2 months.Dompé plans to apply the voucher to its Biologics License Application (BLA) for an intranasal form of Nerve Growth Factor (Cenegermin-bkbj) for the treatment of non-arteritic anterior ischemic optic neuropathy (NAION).Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and the US, announced today its selection by the United States Food and Drug Administration (FDA) to participate in the Commissioner’s National Priority Voucher (CNPV) program. Because of its select

Bentley Systems Announces Winners of the 2025 Going Digital Awards17.10.2025 01:00:00 CEST | Press release

Company also recognizes key projects with Founders’ Honors, the Bentley-Envision winner for infrastructure sustainability, and the 2025 Bentley Educator of the Year (Bentley Systems’ Year in Infrastructure 2025) – Bentley Systems, Incorporated (Nasdaq: BSY), the infrastructure engineering software company, today announced the winners of the 2025 Going Digital Awards. The annual awards honor the extraordinary work of infrastructure professionals and their innovative use of Bentley software to improve the way infrastructure is designed, built, and operated. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251016841527/en/ Bentley Systems announced the winners of the 2025 Going Digital Awards on October 16, 2025 (Photo courtesy of Bentley Systems) This year, nearly 250 projects were nominated by organizations in 47 countries. Winners were selected across 12 categories by a panel of independent judges during Bentley’s Year in Infr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye